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Purpose or Objective: Nowadays stereotactic body radiotherapy (SBRT) is considered a safe and effective approach for several sites of metastatic disease. So far, few published data exist on local control rates of radiotherapy in the context of isolated or limited lymph node metastases. We analyzed the dosimetric and clinical results of oligometastatic patients treated with SBRT for isolated lymph node metastases in abdomen and/or pelvis.
Material and Methods:
In the analysis we included patients with a maximum of 3 lymph node sites of disease with diameter less than 5 cm, located in the abdomen or pelvis. Radiotherapy was administered with Volumetric Modulated Arc Therapy Rapid-Arc (VMAT-RA) and flattening filter-free (FFF) beams; prescribed dose was 45 Gy in 6 fractions of 7.5 Gy each. We analyzed dosimetric data and correlated them with acute toxicity (CTCAE 3.0), local and distant control of disease, progression free survival and overall survival.
Results:
From January 2006 to May 2015, we treated 97 patients with lymph node metastases, of which 26 were lost at follow-up. We analyzed then 71 patients with a total of 79 treated lesions, with a mean follow-up of 1.44 years (range 0.14 -6.21 years). At revaluation, complete response was achieved in 39 (49.3%) lesions and partial response in 28 (35.4%) lesions. Stable disease was demonstrated in 10 (12.6%) cases while only 2 (2.5%) lesions showed progression of disease. The overall clinical benefit rate was 97.5% (77/79 lesions). Acute toxicity was mild: 10 (14%) patients reported G1 toxicity (notably nausea and fatigue); 2 (2.8%) patients reported G2 toxicity (nausea and diarrhea). No Grade 3 and 4 toxicities were reported. In-field progression of disease during follow-up was demonstrated in 18 sites (22.7%) with a median time of 10.7 months. Out-field lymph node progression was demonstrated in 22 (27.8%) cases while distant metastases occurred in 25 (31.6%) cases. Local control rate and overall survival rate at 1 year were 83% and 93%, respectively.
Conclusion:
In consideration of our dosimetric and clinical results, SBRT with VMAT-RA and FFF beams can be considered a safe and effective approach in oligometastatic patients with abdomino-pelvic isolated lymph node metastases. Although this can be considered an initial experience, these results may be potentially significant for preserving quality of life of patients and delaying further systemic treatments.
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The clinical study on oligometastases from different tumors treated with carbon ions X. Wang S682 ESTRO 35 2016 _____________________________________________________________________________________________________ radiotherapy(CIRT) for Oligo-metastatic tumors located different organ from various cancer.
Material and Methods:
From December 2009 to June 2013, 17 patients joined into the clinical study as volunteers. The patients were not surgical candidates for medical reasons or patient refusal. The Oligometastases located in lung,brain and liver respectively from various cancer were treated with CIRT.The heavy ion beams energy was 230~350Mev / u and RBE value was 2.5. A median dose of 60 GyE (range, 20-66 GyE) was delivered to the planning target volume (PTV) in 4-12 fractions with a median daily dose of 5 GyE (range, 4.68-5.5 GyE). Short-term effect was evaluated by tumor change in three months after treatment with RESIST criteria and adverse reactions were determined by criteria of acute radiation injury from Radiation Therapy Oncology Group. Treatment outcome was analyzed in terms of local control rate(LCR), survival rate.
Results: In total, 17 patients (7 lung Oligometastases, 3 liver Oligometastases and 7 brain Oligometastases)with 17 Oligometastatic lesions were treated with CIRT. Until December 2014, median follow-up period was 18 months(2-40ms). Objective response rate was 94.1% to evaluate short-term effect (3CR, 10PR, 3NC, 1PD) .The 1-year LCR and overall survival of the treated patients were 93.3% and 51.0%. Only 1 lung Oligometastases patients relapsed in 7 months after treatment. 1-year Survival rate were 47.6%,66.7%, 75% respectively in brain, lung and liver Oligometastases. Survival rate and LCR were not significantly correlated with Oligometastases location. All treatment-related complications were acute skin reaction and self-limited, without any grade 4-5 toxicity.
Conclusion: ompared with Conventional radiotherapy, CIRT has short treatment time, high Biological effect advantages. CIRT may be one of effective, the least invasive and safe approach to patients with Oligometastases.
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Material and Methods:
From December 2009 to June 2013, 60 patients joined into the clinical study as volunteers. 14 patients with brain tumor〔cerebral glioma(n=6), metastatic brain tumor (n=8)〕,8 patients with head and neck tumor,15 patients with chest tumor〔primary lung cancer (n = 8), metastatic mediastinal carcinoma(n = 1), metastatic lung cancer(n=6)〕,13 patients with abdominal carcinoma〔primary liver cancer(n = 4), pancreatic cancer(n= 1), abdominal soft tissue malignant tumor (n= 3), metastatic liver cancer(n = 4), abdominal lymph node metastasis carcinoma(n = 1)〕,5 patients with pelvic tumor〔rectal cancer(n = 1), anal cancer (n = 1), ovarian carcinoma(n= 1), chordoma(n= 1), soft tissue tumor(n= 1)〕,5 patients with limbs tumor〔skin cancer(n= 2), soft tissue malignant tumor(n=3)〕were treated with carbon ions beams. The beams energy was 230~350Mev / u and RBE value was 2.5. A median dose of 60 GyE (range, 20-66 GyE) was delivered to the planning target volume (PTV) in 4-12 fractions with a median daily dose of 5 GyE (range, 4.68-5.5 GyE). Short-term effect was evaluated by tumor change in three months after treatment with RESIST criteria and adverse reactions were determined by criteria of acute radiation injury from Radiation Therapy Oncology Group.
Treatment outcome was analyzed in terms of local control rate (LCR), survival rate.
Results: Until December 2014, median follow-up period was 18 months (2-40ms). Objective response rate was 98.3% to evaluate short-term effect (9CR, 37PR, 13NC, 1PD) .The 1-year LCR and overall survival of the treated patients were 80.2% and 62.8%. The local control and overall survival rates were not correlated with tumor location and pathological types, the main cause of death was distant metastasis. All treatment related complications were 1-2 grade acute skin reaction (incidence rate = 66.7%) and self-limited, without any grade 4-5 toxicity.
Conclusion:
Carbon ion therapy is safe with respect to toxicity , offers high tumor local control rates and significantly shorten the treatment time. But this study has limitations: a group of cancer patients in advanced stage and short survival and follow up time, small sample size and high heterogeneity because of tumor location, clinical stage and pathological type. More homogeneous prospective data, large multicentric and randomized trials are needed to evaluate the efficacy of heavy ion tumor therapy. 
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